FDA recall, , Moderate risk
Rising Pharmaceuticals Furosemide Tablets
Furosemide Tablets contain a foreign substance.
Summary by Recall Canary from the FDA notice
What happened
Graviti Pharmaceuticals Private Limited, based in Hyderabad, India, began a recall of Furosemide Tablets, USP 40 mg, 1,000 Tablets, Rx Only, on January 10, 2026, because the product contains a foreign substance. The tablets are manufactured for Rising Pharmaceuticals Inc. of East Brunswick, NJ, and distributed nationwide in the U.S.
The recall involves 4,212 bottles of the product. The FDA added the recall to its Enforcement Report on January 21, 2026, and classified it on the same date. The recall was included in the FDA's weekly enforcement report on January 28, 2026.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Furosemide Tablets, USP 40 mg
- NDC
- 64980-563-10
- Lot code
- FUB125042G
Recall details
- Company began the recall
- Sold in
U.S. Nationwide
- Company
- Graviti Pharmaceuticals Private LimitedHyderabad, India
- Hazard
- Foreign object
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 98289
- Recall number
- D-0293-2026
- Quantity recalled
- 4212 bottles
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
In FDA's weekly enforcement report
Listed on Recall Canary
Summary updated
